International Oncology Network - Cancer & Hematology News
March 2012 Blog Posts (4)
First-of-its-kind Clinical Study Explores Novel Non-Invasive Colon Cancer Screening Test
In a first-of-its-kind clinical trial, physician-scientists atUniversity Hospitals Case Medical Center's Seidman Cancer Center and Case Western Reserve University School of Medicine are studying a promising new non-invasive technology for colon cancer screening. The four-year study is recruiting patients to compare the effectiveness of stool DNA (SDNA) testing with colonoscopy for detecting large colon polyps.…
ContinueAdded by Peter Hofland, PhD on March 30, 2012 at 10:30am — No Comments
Melanoma Drugs Receive Initial Positive Clinical Recommendation from pan-Canadian Oncology Drug Review
The Canadian regulatory body, pan-Canadian Oncology Drug Review or pCODR has made an initial recommendation that includes positive clinical evaluations for the treatment of metastatic melanoma, ipilimumab (Yervoy™, Bristol-Myers Squibb)and vemurafenib (Zelboraf®, Genentech). The drugs are…
ContinueAdded by Peter Hofland, PhD on March 30, 2012 at 10:00am — No Comments
The Science of Genomics Helps Point to a New Approach to Faster Anticancer Drug Discovery
Tracking the genetic pathway of a disease offers a powerful, new approach to drug discovery, according to scientists at the University of California, San Diego School of Medicine who used the approach to uncover a potential treatment for prostate cancer, using a drug currently marketed for congestive heart failure. Their findings are published in the current…
ContinueAdded by Peter Hofland, PhD on March 13, 2012 at 5:30pm — No Comments
Directly Injected Novel Viral Vector Designed Kill Brain Cancer Cells While Leaving Healthy Cells Unharmed
Researchers and surgeons working for the Univeristy of California San Diego Moores Cancer Center are among the first in the nation to treat patients with recurrent brain cancer by directly injecting an investigational viral vector into their tumor. The treatment is being developed by a local San Diego Company, Tocagen Inc.
The Toca 511 (vocimagene amiretrorepvec) virus replicates by budding and spreads…
Added by Peter Hofland, PhD on March 1, 2012 at 6:00pm — No Comments
Featured Blog Posts
- Trial of T-Cells Genetically-Engineered to Express an Anti-CD19 Chimeric Antigen Receptor Show Promise as NewTtreatment Approach for B-cell Malignancies
- New Finding Pinpoints a Critical Gene Involved in Melanoma Growth and Provides a Framework for Discovering Ways to Tackle Cancer Drug Resistance
- Personalized Cancer Therapy Requires New Strategies for Cancer Drug Development
- New Discovery Halts Breast Cancer Stem Cells – Suggesting A New Drug Therapy Target
- New Therapy Provide Significant Survival Benefit In Second-line Metastatic Hormone-refractory Prostate Cancer (mHRPC)
- Cancer Tutorial: Introduction to Drug Resistance
- Scientists Unveil Genetic Code for Skin and Lung Cancer
Latest Blog Posts
- Fewer Infections and Less Clotting Associated with Neutral Fluid Displacement Connector
- Erlotinib is the First Personalized Medicine Approved for the Initial Treatment of People with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer
- Angelina Jolie: A Difficult Choice and A Courageous Decision
- Enzastaurin Does Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma Study
- Study Evaluates Treatment of High Dose Aldesleukin + Vemurafenib in Patients with Metastatic Melanoma
- New Diagnostic Test Effectively Predicts Rapid Metastatic Prostate Cancer (RMD) - Outperforms Existing Tools
- UK Charity Calls for More Attention and Awareness for Bladder Cancer
Most Popular Blog Posts
- Newly Identified microRNAs Could be Biomarkers for Early Diagnosis of Progression of Barrett's Esophagus and Esophageal Adenocarcinoma
- Scientific Advisory Board of Patient Advocate Organizations Disagree with Changes to Mammography Guidelines
- First Ever Estimate Reveals the Direct and Indirect Economic Burden of Cancer in Europe
- Angelina Jolie: A Difficult Choice and A Courageous Decision
- Updated Results for BTK Inhibitor Ibrutinib (PCI-32765) Shows Prolonged Progression Free Survival in High Risk, Advanced CLL/SLL and MCL Patients
- Expense and Unaffordable Leukemia Treatment May Harm Patients
- PD-L1 Antibody MPDL3280A is well Tolerated in Phase I Study - No Limiting Toxicities Across a Range of Cancer Types
Blog Topics by Tags
Monthly Archives
2013
2012
- December (32)
- November (19)
- October (17)
- September (9)
- August (10)
- July (4)
- June (29)
- May (16)
- April (6)
- March (4)
- February (21)
- January (38)
2011
- December (47)
- November (32)
- October (21)
- September (32)
- August (18)
- July (23)
- June (83)
- May (45)
- April (54)
- March (36)
- February (62)
- January (43)
2010
- December (58)
- November (49)
- October (65)
- September (23)
- August (7)
- July (4)
- June (34)
- May (7)
- April (7)
- March (5)
- February (3)
- January (6)
2009
2008
- December (19)
2007
- April (1)
2005
2004
- September (1)
2001
- November (1)
ADVERTISEMENT
Bookmark / Share
Join the Conversation!
© 2013 Created by Peter Hofland, PhD.
